上海优宁维生物科技股份有限公司 2025 年半年度报告全文 证券代码：301166 证券简称：优宁维 公告编号：2025-068 上海优宁维生物科技股份有限公司 2025 年半年度报告 2025 年 8 月 1 上海优宁维生物科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人冷兆武、主管会计工作负责人唐敏及会计机构负责人(会计主 管人员)陆志文声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展规划等前瞻性事项的陈述，属于计划性事项，不 构成公司对投资者的实质承诺，投资者和相关人士均应对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异。 公司可能面临的风险详见本报告"第三节管理层讨论与分析"之"十、公司 面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第二节 | 公司简介和主要财务指 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-065 上海优宁维生物科技股份有限公司 第四届董事会第七次会议决议公告 2、审议并通过《2025 年半年度募集资金存放与使用情况的专项报告》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 上海优宁维生物科技股份有限公司（以下简称"公司"）第四届董事会第七次 会议（以下简称"本次会议"）于 2025 年 8 月 24 日以现场结合通讯方式召开。会 议通知已于 2025 年 8 月 14 日以电子邮件方式送达全体董事。会议应出席的董事 9 人，实际出席会议的董事 9 人。本次会议由董事长冷兆武先生主持，公司高管 及监事列席会议。本次会议的召集、召开和表决程序符合法律、法规及《公司章 程》的规定。 二、会议审议情况 1、审议并通过《2025 年半年度报告及摘要》 经审议，董事会认为：公司《2025 年半年度报告》及《2025 年半年度报告 摘要》编制符合法律、法规、中国证监会和深圳证券交易所的相关规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或 ...

格隆汇8月18日丨优宁维(301166.SZ)公布，公司("受让方")为加快在生命科学服务领域的上下游布局， 实现在生命科学领域的产业拓展和技术补强，近日与上海睿昂基因科技股份有限公司(简称"出让 方"或"睿昂基因")、上海弘盛君浩股权投资基金管理有限公司(简称"弘盛君浩"或"基金管理人")共同签 署了《基金份额转让协议》，以人民币0元受让睿昂基因持有的上海弘盛厚德私募投资基金合伙企业(有 限合伙)(简称"弘盛厚德"或"合伙企业")财产份额1,500万元(实缴出资0元)。本次转让完成后，公司成为 弘盛厚德有限合伙人之一，投资后公司认缴额占合伙企业总认缴额的2.6283%。 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-064 上海优宁维生物科技股份有限公司 关于受让投资基金份额暨对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、投资概述 上海优宁维生物科技股份有限公司（以下简称"公司"或"受让方"）为加快 在生命科学服务领域的上下游布局，实现在生命科学领域的产业拓展和技术补强， 近日与上海睿昂基因科技股份有限公司（以下简称"出让方"或"睿昂基因"）、 上海弘盛君浩股权投资基金管理有限公司（以下简称"弘盛君浩"或"基金管理 人"）共同签署了《基金份额转让协议》，以人民币0元受让睿昂基因持有的上 海弘盛厚德私募投资基金合伙企业（有限合伙）（以下简称"弘盛厚德"或"合 伙企业"）财产份额1,500万元（实缴出资0元）。本次转让完成后，公司成为弘 盛厚德有限合伙人之一，投资后公司认缴额占合伙企业总认缴额的2.6283%。 根据《深圳证券交易所创业板股票上市规则》《公司章程》《总经理工作细 则》等有关规定，本次投资属于总经理办公会议审批权限，无需提交董事会、股 东大会审议。本次对外投资不构成关联交易，亦不 ...

格隆汇8月13日丨优宁维(301166.SZ)于近期投资者关系活动表示，公司自主品牌整体毛利率约为50%， 2024年公司自主品牌合计收入同比增长近30%，保持较好增长趋势。目前自主品牌收入占比较低。后续 随着公司加大对自主品牌的销售资源投入和产品管线的不断丰富，自主品牌收入占比有望提升。 ...

Group 1: Financial Performance - The overall gross margin for the company's proprietary brands is approximately 50% [1] - Revenue from proprietary brands is expected to grow nearly 30% year-on-year by 2024, indicating a strong growth trend [1] - The current revenue share from proprietary brands is relatively low, but is anticipated to increase with enhanced sales resource investment and product pipeline expansion [1] Group 2: Research and Development - The company is focusing its R&D investments primarily in the fields of antibodies and proteins [1] - As of the end of 2024, the Hangzhou antibody R&D center has developed over 2,900 SPUs (Standard Product Units) including paired antibodies and diagnostic antibodies [1] - The Nanjing protein R&D center has developed over 1,700 SPUs, including drug targets and cytokines, and has introduced new products like one-step Elisa kits [1] Group 3: Share Repurchase and Incentive Plans - In 2024, the company initiated a share repurchase plan, utilizing 25,987,076 CNY to buy back 927,600 shares, intended for equity incentives or employee stock ownership plans [1] - A new share repurchase plan is set to use between 15 million and 30 million CNY of its own funds for share buybacks aimed at capital reduction [1][2] - Future equity incentive plans will be introduced based on business development needs to enhance motivational effects [2] Group 4: Mergers and Acquisitions Strategy - The company aims to strengthen channel and R&D capabilities to better serve customers and provide diverse product offerings [2] - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [2]

证券代码：301166 证券简称：优宁维 公告编号：2025-063 上海优宁维生物科技股份有限公司 关于注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海优宁维生物科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册， 并经深圳证券交易所同意，上海优宁维生物科技股份有限公司（以下简称"公司"） 首次公开发行人民币普通股（A 股）股票 2,166.6668 万股，每股面值为人民币 1.00 元，发行价格为人民币 86.06 元/股，募集资金总额为人民币 186,463.34 万元， 扣除发行费用人民币 26,911.62 万元（不含税）后，实际募集资金净额为人民币 159,551.73 万元。 | 账户名称 | 开户银行 | 专户账号 | 注销前账户余额（元） | | --- | --- | --- | --- | | 公司 | 招商银行股份有限公司上海四平支行 | 121923691110118 | 0 | | 公司 | 中国民生 ...

Core Viewpoint - The company is positioned as a one-stop service provider in life sciences, focusing on integrating both domestic and international brands to meet customer needs, with a significant growth in its own brand products expected in the future [1][2]. Product Structure - The company offers a range of products and services including reagents, consumables, instruments, and laboratory services, primarily focusing on agency products supplemented by its own brand products [1]. - In 2024, the revenue from the company's own brand products is expected to grow nearly 30% year-on-year, indicating a strong growth trend [2]. Profitability and Revenue Growth - The overall gross margin for the company's own brand products is approximately 50%, with a low current revenue share from these products [2]. - The company plans to increase the revenue share of its own brand products by investing more resources into sales and expanding its product pipeline [2]. Shareholder Incentives - In 2024, the company initiated a share repurchase plan, utilizing 25,987,076 yuan to buy back 927,600 shares, which will be used for equity incentives or employee stock ownership plans [3]. - Future equity incentive plans will be introduced based on business development needs to enhance motivation [3]. International Market Expansion - The company's operations are primarily domestic, but it plans to accelerate the internationalization of its own brand products based on R&D and domestic sales performance, including establishing overseas subsidiaries [4]. - The company has already set up a subsidiary in Singapore in 2024 and is actively enhancing product visibility through online marketing and participation in offline exhibitions [4]. M&A Strategy - The company aims to strengthen its channel and R&D capabilities to better serve customers and provide a diverse range of products and services [5]. - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [5].

Group 1 - The stock price of You Ning Wei is 34.05 yuan, down 0.21 yuan from the previous trading day, with a trading range of 33.73 yuan to 34.55 yuan and a trading volume of 15,874 hands, amounting to 54 million yuan [1] - You Ning Wei operates in the biopharmaceutical industry, focusing on the research, production, and sales of life science reagents and related products, with headquarters in Shanghai [1] - As of August 4, You Ning Wei was surveyed by one fund company, and among the six companies surveyed that day, its total market capitalization was less than 10 billion yuan [1] Group 2 - On August 5, the net outflow of main funds from You Ning Wei was 2.0785 million yuan, accounting for 0.11% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 3.3885 million yuan, representing 0.18% of the circulating market value [1]

市场表现上，基金调研股中，近5日上涨的有5只，涨幅居前的有威尔高、优宁维、科士达等，涨幅为 5.59%、2.10%、1.54%；下跌的有1只，跌幅居前的有中旗新材等，跌幅为4.35%。 业绩方面，基金调研公司中，公布上半年业绩预告的共有2家，业绩预告类型来看，预增有1只。以净利 润增幅中值来看，净利润增幅最高的是威尔高，预计净利润中值为4650.00万元，同比增幅为21.71%。 （数据宝） 8月4日基金调研公司一览 昨日基金共对6家公司进行调研，扎堆调研东威科技、泰恩康等。 证券时报·数据宝统计，8月4日共8家公司被机构调研，按调研机构类型看，基金参与6家公司的调研活 动。东威科技最受关注，参与调研的基金达59家；泰恩康、威尔高等分别获38家、3家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有2家，创业板公司有3家，科创板公司有1 家。 从基金调研公司的A股总市值统计，总市值不足100亿元的有3家，分别是优宁维、威尔高、中旗新材 等。 | 代码 | 简称 | 基金家数 | 最新收盘价（元） | 近5日涨跌幅（%） | 行业 | | --- | --- | --- | --- | --- ...